Axel Grothey, MD, is the director of GI Cancer Research at the West Cancer Center, University of Tennessee, in Memphis, Tennessee. Dr. Grothey’s clinical interests focus on gastrointestinal cancers, in particular colorectal cancer, antiangiogenesis, signal transduction inhibitors, and clinical trial design and statistics. He currently co-chairs the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee after having served as chair of the Colon Cancer Task Force for six years. Dr. Grothey is a member of the National Comprehensive Cancer Network (NCCN) Guidelines Committee for Colon, Rectal, and Anal Cancer and a member of the European Society of Medical Oncology (ESMO) Guidelines Committee for Colorectal Cancer.
He performs journal review and editorial activities for numerous medical journals and is editor for
Clinical Colorectal Cancer
,
Emerging Cancer Therapeutics
,
Practice Updates
, and
Therapeutic Advances in Medical Oncology
. Dr. Grothey serves on the editorial boards of the
Journal of Clinical Oncology
and
Journal of the National Cancer Institute
. He has given numerous international, national, and regional presentations, as well as invited and visiting professor presentations. He has co-authored more than 500 articles, books, book chapters, editorials, abstracts, and letters.
Dr. Grothey received his medical degree at Ruhr-Universität Bochum, Germany, and completed residencies at West German Tumor Center and the Institute of Pathology at the University of Essen and a residency and fellowship at the University of Bochum.
